Allen Lee Cohn - Concepedia

Author

Allen Lee Cohn

Rocky Mountain Cancer Centers

Also Known As

A COHN, A Cohn, A L Cohn, A. Cohn, A. L. Cohn, A.L. Cohn, ALLEN COHN, Allen Cohn, Allen L Cohn, Allen L. Cohn

230

Publications

15K

Citations

H-Index

Concepts

All Affiliations

Rocky Mountain Cancer Centers Texas Oncology Sarah Cannon Memorial Sloan Kettering Cancer Center The University of Texas MD Anderson Cancer Center

About

Allen Lee Cohn is an author at Rocky Mountain Cancer Centers specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	55	6.3K
2	Health Sciences	17	19	3.2K
3	Cell Biology	3	3	75
4	Public Health	1	1	17
5	Emergency Medicine	1	1	21

Allen Lee Cohn

Publications

14.5K

Citations

H-Index

Page 1

	Year	Citations
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial Andrew X. Zhu, Richard S. Finn, Julien Edeline, The Lancet Oncology Open-label Phase 2HepatologyMedicineClinical TrialsPathology	2018	2.5K
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA M.C. Liu, Geoffrey R. Oxnard, Eric A. Klein, Annals of Oncology	2020	1.4K
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study Josep Tabernero, Takayuki Yoshino, Allen Lee Cohn, The Lancet Oncology OncologyColorectal CancerPathologyRamucirumab Versus PlaceboPharmacotherapy	2015	938
Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set Eric A. Klein, Donald Richards, Allen Lee Cohn, Annals of Oncology	2021	872
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer J. Randolph Hecht, Edith P. Mitchell, Tarek Chidiac, Journal of Clinical Oncology	2008	851
Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study Howard S. Höchster, Lowell L. Hart, Ramesh K. Ramanathan, Journal of Clinical Oncology	2008	620
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor William D. Tap, Zev A. Wainberg, Stephen P. Anthony, New England Journal of Medicine	2015	571
Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines Heinz‐Josef Lenz, Eric Van Cutsem, Shirin Khambata‐Ford, Journal of Clinical Oncology	2006	536
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer Vicky Makker, Matthew H. Taylor, Carol Aghajanian, Journal of Clinical Oncology	2020	512
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial Vicky Makker, Drew Rasco, Nicholas J. Vogelzang, The Lancet Oncology Advanced Endometrial CancerInterim AnalysisMedicineGynecologyCancer Treatment	2019	470

Page 1